Singapore HSA Therapeutic Products Branch has extended the application of electronic labelling (e-labelling) to Pharmacy-only (P) and General Sale List (GSL) medicines with effect from 30 June 2026.
This is in addition to Prescription-only medicines (POM), for which e-labelling is already applicable. Companies may opt to replace the physical Patient Information Leaflet (PIL) with e-PIL.
For eligibility criteria and documentary requirements applicable to P and GSL medicines, please refer to updated guideline Appendix 7A: Guidance on Electronic Labelling for Therapeutic Products at the following link: https://file.go.gov.sg/guidance-electronic-labelling-tp.pdf
This update provides companies with greater flexibility in meeting Singapore’s labelling requirements while reducing reliance on physical PILs.